US Stock MarketDetailed Quotes

IKT Inhibikase Therapeutics

Watchlist

1.7100
-0.1900-10.00%

Close Apr 26 16:00 ET

1.6906
-0.0194-1.13%

Post 16:01 ET

11.08MMarket Cap-478P/E (TTM)

Inhibikase Therapeutics Stock Forum

Ant-waan

Apr 25 01:44

$Inhibikase Therapeutics(IKT.US)$ In progress 😎

Share Your Today's Profit/Loss

Ant-waan

Apr 23 17:38

$HWH International (HWH.US)$ Hello Traders in the world Good Luck to you all 👋 $Nuwellis (NUWE.US)$ $Serve Robotics (SERV.US)$ $NewGenIvf (NIVF.US)$ $Lion Group(LGHL.US)$$ReShape Lifesciences(RSLS.US)$$Spectral AI(MDAI.US)$$Inhibikase Therapeutics(IKT.US)$$Shimmick(SHIM.US)$$HWH International(HWH.US)$

Trytosaveabit

Apr 19 04:31

Make a note!

$Inhibikase Therapeutics(IKT.US)$ Inhibikase Therapeutics - Upon Completion of Double-Blinded Phase of 201 Trial, We Expect to Request an End of Phase 2 Meeting With FDA by End of 2024

Trytosaveabit

Apr 3 20:11

Update

$Inhibikase Therapeutics(IKT.US)$ Inhibikase Therapeutics Announces Apr. 5 Pre-IND Meeting With FDA For IkT-001Pro In Pulmonary Arterial Hypertension
Benzinga· 3 mins ago

Trytosaveabit

Feb 7 21:13

$Inhibikase Therapeutics(IKT.US)$ Inhibikase Reports Preliminary Outcomes Of Pre-NDA Meeting With FDA On Pathway For Approval For IkT-001Pro In Blood And Gastrointestinal Cancers; Says Given Specific Guidance On Manufacturing Requirements Necessary To Complete NDA

Trytosaveabit

Jan 29 22:08

Update

$Inhibikase Therapeutics(IKT.US)$ Inhibikase Therapeutics Announces Publication Highlighting Results From Its Phase 1 Studies With Risvodetinib

Moo Top

Jan 6 08:42

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall